Impact of Postprandial 'Exercise Snacks' on Protein and Glucose Metabolism Following a Period of Step Reduction in Older Adults

July 11, 2023 updated by: Daniel Moore, University of Toronto

The Impact of Postprandial 'Exercise Snacks' on Protein and Glucose Metabolism Following a Period of Step Reduction in Older Adults

The purpose of this study is to assess the impact of 3-days reduced physical activity (<1500 steps/day) with/without 'exercise snacks' (15 chair stands with calf raises every 30 min) on skeletal muscle metabolic health.

Study Overview

Detailed Description

Many adults gradually lose muscle size, strength, and function after the age of 50. These losses are believed to occur faster with periods of reduced activity (e.g., lower step counts or physical movement when sick or injured) and can be difficult to regain by merely returning to a previously normal activity status. Such periods of reduced activity can also impair the body's ability to use the nutrients in the food consumed (e.g., proteins and carbohydrates), which increases the risk of frailty, type 2 diabetes, and ultimately a reduced quality of life. It is important to identify strategies to prevent these losses in muscle size, strength, and function especially during periods of reduced activity.

Recently, our laboratory has found that performing repeated bodyweight chair squats (repeated sit-to-stands with a calf raise) during a single day of reduced activity improves the muscle's ability to use carbohydrates and proteins, which may be a viable strategy to offset the negative effects of step reduction on muscle health.

In this study, the investigators will assess whether completing bodyweight chair squats at regular intervals (i.e., 'exercise snacks') reduces the negative effects of step reduction on carbohydrate and protein metabolism following a meal. The investigators will determine the impact of 'exercise snacks' (15 chair stands with calf raises every 30 min) compared to seated rest on protein and carbohydrate metabolism following three days of step reduction. The investigators will also assess how these responses compare to those seen following three days of normal (i.e., habitual) activity.

Study Type

Interventional

Enrollment (Estimated)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Healthy older (age: 60-80 y) adults
  • BMI between normal to overweight (18.5-29.9 kg/m2)

Exclusion Criteria:

  • Regular use of nonsteroidal anti-inflammatory drugs (with the exception of daily low-dose aspirin)
  • Alcohol consumption during the study period
  • Use of anticoagulants
  • Use of a walker, cane, or assistive walking device
  • Current or recently remised cancer
  • Infectious or gastrointestinal disease
  • Inability to comply with study protocol (e.g., >1,500 steps/day during Step-Reduction Phase)
  • Regular tobacco use
  • Self-reported illicit drug use (e.g. growth hormone, testosterone, etc.)
  • Diagnosed chronic illness (e.g. type 2 diabetes, heart disease, thyroid disease)
  • Hormonal Replacement Therapy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Habitual Activity
Following three days of habitual activity, a metabolic trial will be completed wherein participants (10M/10F) will be assessed for their anabolic response to a protein-carbohydrate meal.
Participants will undergo a metabolic trial to assess for their anabolic response to a protein-carbohydrate meal.
Experimental: Step-Reduction
Participants will undergo three days of reduced physical activity (<1,500 steps/day) prior to a metabolic trial to establish their anabolic response to a protein-carbohydrate meal.
Participants will undergo a metabolic trial to assess for their anabolic response to a protein-carbohydrate meal.
Participants (n=10; 5F/5M) will be randomized to perform 15 sit-to-stands with calf raises every 30 minutes for the 4 hour duration between muscle biopsies
Other Names:
  • Exercise Snacks

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Myofibrillar protein synthesis rates
Time Frame: 5 Hours
Myofibrillar protein synthesis rates assessed by incorporation of oral stable isotope tracer in both arms.
5 Hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Whole-body protein turnover
Time Frame: 5 Hours
Whole-body protein turnover assessed by oral stable isotope tracers in both arms.
5 Hours
Amino acid oxidation and net protein balance
Time Frame: 5 Hours
Amino acid oxidation and net protein balance assessed by oral tracers in both arms. Net protein balance is derived from the difference between amino acid intake (known) and total amino acid oxidation over the 5h measurement period.
5 Hours
Postprandial insulin area under the curve (AUC) to mixed macronutrient breakfast
Time Frame: 5 Hours postprandial
The plasma insulin concentration measured by enzyme-linked immunosorbent assay (ELISA) area under the curve (AUC) will be quantified using the trapezoidal rule.
5 Hours postprandial
Postprandial glucose area under the curve (AUC) to mixed macronutrient breakfast
Time Frame: 5 hours postprandial
The plasma glucose concentration measured by hexokinase method area under the curve (AUC) will be quantified using the trapezoidal rule.
5 hours postprandial

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Hugo JW Fung, PhD, University of Toronto
  • Principal Investigator: Daniel R Moore, PhD, University of Toronto

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 1, 2023

Primary Completion (Estimated)

March 1, 2024

Study Completion (Estimated)

August 1, 2024

Study Registration Dates

First Submitted

February 21, 2023

First Submitted That Met QC Criteria

March 30, 2023

First Posted (Actual)

April 12, 2023

Study Record Updates

Last Update Posted (Actual)

July 13, 2023

Last Update Submitted That Met QC Criteria

July 11, 2023

Last Verified

July 1, 2023

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Nervous System Diseases

Clinical Trials on Metabolic Trial

Subscribe